Subscribe To
Anavex®2–73 (blarcamesine) phase 2b/3 study met primary and key secondary endpoints, showing statistically significant reduction of clinical decline in global clinical study of patients with early alz
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in cognitive Function ...
December 2, 2022, 1:26 am
Anavex®2–73 (blarcamesine) phase 2b/3 study met primary and key secondary endpoints, showing statistically significant reduction of clinical decline in global clinical study of patients with early alz
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in cognitive Function ...
December 2, 2022, 1:26 am
Biogen's (biib) lecanemab shows benefit but with side effects
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rat...
November 30, 2022, 10:32 am
Wellbeing digital sciences subsidiary kgk science submits psilocybin and fragile x syndrome clinical trial application for client nova mentis
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly-owned subsidiary KGK Science Inc has submitted a clinical trial applicatio...
November 30, 2022, 9:21 am
Biogen stock up 3% premarket after update on alzheimer's treatment; stifel reiterates buy rating
Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimenta...
November 30, 2022, 6:48 am
: a new alzheimer’s treatment may help some patients, though researchers say more safety data is needed
A new study found that Eisai and Biogen’s experimental Alzheimer’s drug moderately reduced cognitive...
November 30, 2022, 1:29 am
Eisai, biogen alzheimer's drug slows cognitive decline, safety for some becomes focus
New data was presented on Tuesday....
November 29, 2022, 7:55 pm
Verses announces proposed warrant amendments
VANCOUVER, British Columbia, Nov. 25, 2022 (GLOBE NEWSWIRE) — VERSES Technologies Inc. (NEO:VERS) (“VERSES” or the “Company”), a ...
November 25, 2022, 9:30 pm
Ericsson (eric) to boost 6g research capabilities in the uk
The initiative by Ericsson (ERIC) is likely to sow the seeds for in-depth 6G research activities on hardware security, AI, ...
November 22, 2022, 9:47 am
Ericsson to invest in 6g network research in britain
Networks equipment maker Ericsson said it would invest millions of pounds in 6G mobile research in Britain, working with universities on hardware secu...
November 22, 2022, 4:01 am
Inmune bio, high risk, higher reward.
The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities...
November 21, 2022, 12:45 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm